¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"clinical syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
¿µ¹® nephrotic syndrome ÇÑ±Û ÄáÆÏÁõÈıº
¼³¸í   
  ÄáÆÏÀÇ Å丮À̻󿡠ÀÇÇÑ ´Ü¹éÁú¼Õ½ÇÀÌ ÁÖ¿øÀÎÀΠº´ÀÌ´Ù. ±× Á¤ÀǴ ¼ºÀÎÀÇ ¿ä´Ü¹é·®(¼Òº¯¿¡ ¼¯¿© ³ª¿À´Â ´Ü¹éÁúÀÇ ¾ç. ´ë°³ Á¤»óÀο¡¼­´Â ³ª¿ÀÁö ¾Ê°Å³ª, È¤Àº ¾ÆÁÖ ¼Ò·®ÀÌ ³ª¿Ã »ÓÀÓ)ÀÌ ÇÏ·ç 3.5mgÀÌ»ó, ¶ÇÇÑ ¼Ò¾Æ¿¡¼­´Â Ç÷Áß ¾ËºÎ¹Î³óµµ°¡ 2.5mgÀÌÇÏ, ÇÏ·íµ¿¾È ¼Òº¯À¸·Î ³ª¿À´Â ¿ä´Ü¹é·®À» ½Ã°£´ç °è»êÇßÀ» ¶§ ½Ã°£´ç 40mgÀÌ»óÀΠ°æ¿ìÀÌ´Ù. µû¶ó¼­ ÄáÆÏÁõÈıºÀ̶õ À§ÀÇ Á¤ÀÇ¿¡ ÇÕ´çÇϱ⸸ Çϸ頸ðµÎ ÇØ´çµÇ¹Ç·Î, ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇÑ ÄáÆÏÀÌ»óÀ¸·Î¼­ ´Ü¹éÁúÀÇ Áö³ªÄ£ ¹èÃâÀ» ³ªÅ¸³»´Â Áúº´ÀÇ ÁýÇÕü¸¦ ¶æÇÑ´Ù. ´ë°³ Áõ»óÀº Áö³ªÄ£ Ç÷ÁߴܹéÁúÀÇ °¨¼Ò·Î ÀÎÇÑ ºÎÁ¾, ±×¸®°í ÀÌÂ÷ÀûÀΠÁõ»óÀ¸·Î ¹ß»ýÇÑ °íÁöÁúÇ÷Áõ, °¨¿°°¨¼ö¼ºÀÇ Áõ°¡, °íÇ÷¾Ð µîÀÌ´Ù. Ä¡·á¿Í ¿¹ÈĴ ÄáÆÏÁõÈıºÀ» ³ªÅ¸³»´Â °¢ ¿øÀο¡ µû¶ó ´Ù¸£³ª, ´ë°³ ¼Ò¾Æ¿¡ ¹ß»ýÇÑ °æ¿ì ½ºÅ×·ÎÀ̵åÁ¦Àç¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù.
¿µ¹® Cushing's syndrome ÇÑ±Û Äí½ÌÁõÈıº
¼³¸í   
  Äí½ÌÁõÈıºÀ̶õ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ¸¸¼ºÀûÀ¸·Î °úÀ׺кñ¿¡ ÀÇÇØ¼­ ÀϾ´Â º´À» ¸»ÇÑ´Ù.
  
  ¿øÀÎÀ¸·Î ¨ç ³úÇϼöü¿¡¼­ ACTH°¡ °úÀ× ºÐºñµÇ´Â °æ¿ì: ³úÇϼöü¿¡¼­ ACTH°¡ ³Ê¹«³ª ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì¿¡ ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨è ³úÇϼöü ÀÌ¿ÜÀÇ ºÎºÐ¿¡¼­ ACTH°¡ ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì: Æó¾Ï, ³­¼Ò¾Ï µîÀÇ Á¾¾ç¿¡¼­ ACTH¸¦ »ý»êÇϴ °æ¿ì°¡ ÀÖ´Ù. ÀÌ °æ¿ì¿¡µµ ¿ª½Ã ºÎ½ÅÇÇÁúÀÌ ÀÚ±ØÀÌ µÇ¾î¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨é ACTHÀÇ ÀÚ±ØÀÌ ¾øÀÌ ºÎ½Å¿¡¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ³ª¿À´Â °æ¿ì. ACTHÀڱؿ¡ °ü°è¾øÀÌ ºÎ½ÅÇÇÁúÀÇ °úÀ×¼ºÀå, Á¾¾ç¿¡ ÀÇÇØ¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÇ´Â °æ¿ì. ¨ê ¿ÜÀμº, ÀÇÀμº: Ä¡·á¸¦ À§Çؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵带 Àå±â Åõ¿©ÇÒ °æ¿ì¿¡ »ý±â´Â Äí½ÌÁõÈıº
  
  Äí½ÌÁõÈıº¿¡¼­ Æ¯È÷ ¨ç¹ø¿¡ ÇØ´çÇϴ °ÍÀ» Äí½Ìº´¶ó°í ÇÑ´Ù.
  
  Áõ»óÀº ¶×¶×ÇÏ°í ¾ó±¼ÀÌ ´Þµ¢ÀÌó·³ µÕ±Û°í »ìÀÌ ÂÈÁö¸¸ ÆÈ, ´Ù¸®´Â °¡´Ã°í ´ë½Å¿¡ ¸ö¿¡ ¸¹Àº »ìÀÌ ºÙ¾îÀÖ´Ù. ¸ñµÚ¿¡ ¸¹Àº »ìÀÌ À־ ±×°ÍÀÌ µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ ÇÑ´Ù. À̰ÍÀº ¿ø·¡ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 Áö¹æÀ» ºÐÇØÇϴ ¿ªÇÒÀ» ÇÏÁö¸¸ º´ÀûÀ¸·Î ¸¹ÀÌ ³ª¿Ã °æ¿ì¿¡´Â Áö¹æÀÇ ºÐÆ÷¸¦ º¯È­½Ã۴ ¿ªÇÒÀ» Çϱ⠶§¹®ÀÌ´Ù. Áï ÆÈ, ´Ù¸® µîÀÇ ¿Â¸ö¿¡ ÆÛÁ®Àִ Áö¹æÀ» ¸öÅëÂÊÀ¸·Î ¸ðµÎ À̵¿½ÃŲ´Ù. ÀÜÅÐÀÌ ¿Â¸ö¿¡ °ÉÃļ­ ¸¹ÀÌ ³ªÀÖ°í ¿©µå¸§ÀÌ ¸¹°í ¹è¿¡ ÀÚÁÖ»ö ¼±Á¶°¡ Àִ °æ¿ì°¡ ¸¹´Ù. ±×¸®°í ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ´Ü¹éÁúÀ» ºÐÇØÇØ¼­ ´ç·ù¸¦ ¸¸µå´Â ¿ªÇÒÀ» ÇÏ¿© ±ÙÀ°À̳ª »À´ëÀÇ ½ÉÇÑ ¼Ò½ÇÀÌ ÀÖ´Ù. ±×·¡¼­ ±ÙÀ°ÀÌ °ÅÀÇ ¾ø¾îÁö°í »À´Â ¾ÆÁÖ ºÎ·¯Áö±â ½±°Ô µÈ´Ù. ´ë°³ °íÇ÷¾ÐÀΠ°æ¿ì°¡ ¸¹°í ½É¸®ÀûÀ¸·Î ¿ì¿ïÁõÀ̳ª °ú¹Î¼º µîÀÌ ÀÖÀ» ¼öµµ ÀÖ°í ½ÉÇÑ °æ¿ì¿¡´Â Á¤½Åº´Áõ¼¼¸¦ º¸À̱⵵ ÇÑ´Ù.
¿µ¹® Klinefelter syndrome ÇÑ±Û Å¬¶óÀÎÆçÅÍÁõÈıº
¼³¸í   
  1942³â H.F. Å¬¶óÀÎÆçÅͰ¡ ±âÀçÇÑ ¼º¿°»öüÀÌ»óÁõÈıº. Á¤»óÀÎÀÇ ¼º¿°»öüÇüÀº ³²¼º XY, ¿©¼º XX¸¦ ³ªÅ¸³»Áö¸¸, ÀÌ ÁõÈıº¿¡¼­´Â ¼º¿°»öüÇüÀÌ XXY. XXYY, XXXXY µîÀÇ ¿©·¯ °¡Áö ÀÌ»óÇÑ ÇüŸ¦ ³ªÅ¸³½´Ù. ¿Ü¼º±â-ü°Ý-¼ºÂ¡ µîÀǠƯ¡ÀûÀΠÁõ¼¼·Î º¼ ¶§¿¡ ¿ÏÀüÇÑ ³²¼ºÀÌ °áÈ¥ÇÏ¿© ¼º»ýȰ±îÁö ÇÏ¿´À¸³ª, ÀÚ½ÄÀÌ ¾øÀÚ ºÎºÎ°¡ ÇÔ²² º´¿øÀ» Ã£¾Æ°¡¼­ ¿°»öü¸¦ °Ë»çÇØ º¸°í ³²ÀÚ¿¡°Ô ÀÌ ÁõÈıºÀÌ ÀÖÀ½À» ¾Ë°Ô µÇ´Â °æ¿ì°¡ ¸¹´Ù. ÀÌ ¹Û¿¡ ¼ºÀÎÀÌ µÇ¾î ³ªÅ¸³ª´Â ÁÖ¿ä Áõ¼¼¸¦ µé¸é, ÀÛÀº°íȯ, ¿©¼ºÇü À¯¹æÁõ, ¹«Á¤ÀÚÁõ, ºÒÀÓ, ¿äÁß °í³ªµµÆ®·ÎÇÉÀÇ »ó½Â, Áö´É ÀúÇÏ µîÀÌ´Ù. Ä¡·á´Â 2Â÷ ¼ºÂ¡ÀÇ ÃËÁøÀ» À§ÇÏ¿© È£¸£¸ó¿ä¹ý¿¡ ÀÇÇÑ ³²¼ºÈ­¸¦ ½ÃµµÇÑ´Ù.
¿µ¹® fetal alcohol syndrome ÇÑ±Û Å¾ƾËÄÚ¿ÃÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼­ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ÂªÀº°Ë¿­, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù.
¿µ¹® Horner syndrome ÇÑ±Û È£¸£³ÊÁõÈıº
¼³¸í   
  ±³°¨½Å°æ°æ·ÎÀÇ Àå¾Ö·Î »ý±â´Â º´ÀÌ´Ù. ±³°¨½Å°æÀº ÀÚÀ²½Å°æÀÇ Çϳª·Î ¿Â¸ö¿¡ ºÐÆ÷¸¦ ÇÑ´Ù. Æ¯È÷ ¾ó±¼ÂÊ¿¡´Â ´«²¨ÇÃÀ» ¿Ã¸®´Â ±ÙÀ°°ú ¶¡»ù¿¡ ºÐÆ÷Çϰí ÀÖ´Ù. À̿͠°°Àº ±³°¨½Å°æÀÇ ÀÛ¿ëÀ¸·Î ´«²¨Ç®À» Á¤»óÀûÀ¸·Î ¿Ã¸®°í ¾ó±¼¿¡ ¶¡ÀÌ ³ª¿À°Ô µÈ´Ù. ±× ¿Ü¿¡µµ ´«ÀÇ ºûÀÇ ¾çÀ» Á¶ÀýÇϴ ȫ並 ¼öÃà½Ã۴ ±ÙÀ°¿¡ ºÐÆ÷ÇØ¼­ ±× ÀÛ¿ëÀ¸·Î ´«ÀǠȫä°¡ ¼öÃàÇÏ¿© µ¿°øÀÌ Ä¿Áö°Ô µÈ´Ù. ±³°¨½Å°æÀº ±× ±â¿øÀÌ ´ë³ú¼Ó¿¡ Á¸ÀçÇϴ ½Ã»óÇϺζó´Â °÷À̰í À̰÷¿¡¼­ ½ÃÀÛÇÑ ±³°¨½Å°æÀº Ã´¼ö¸¦ Å¸°í ³»·Á¿Í¼­ ¸ñºÎÀ§¿¡¼­ Ã´¼ö¸¦ ºüÁ®³ª¿Í¼­ ±³°¨½Å°æÀ» Áٱ⸦ Çü¼ºÇÏ¿© ´Ù½Ã ³ú·Î °¡´Â Ç÷°üÀ» µû¶ó¼­ ¾ó±¼ÂÊÀ¸·Î °¡°ÔµÈ´Ù. ¸¸¾à ÀÌ ±³°¨½Å°æÀÇ ÁÖÇàºÎÀ§¿¡ º´º¯ÀÌ »ý±â¸é ±×ÂÊÀÇ ¾ó±¼¿¡ ±³°¨½Å°æÀÌ Â÷´ÜµÇ¹Ç·Î º´ÅÍÂÊÀÇ ´«ÀÇ ´«²¨Ç®ÃÄÁü, Ãൿ ±×¸®°í º´º¯Ãø ¾ó±¼ºÎÀÇ ¶¡ÀÌ ³ªÁö ¾Ê´Â °Í µîÀÇ Áõ»óÀ» ³ªÅ¸³ª°Ô µÈ´Ù. ÀÌ·± Çö»óÀ» È£¸£³ÊÁõÈıºÀ̶ó°í ÇÑ´Ù. À̰ÍÀº ¿©·¯ °¡Áö º´¿¡¼­ ³ªÅ¸³¯ ¼ö°¡ Àִµ¥ ³ú³ª Ã´¼öÀÇ ÁúȯÁß¿¡¼­ ÀÌ ±³°¨½Å°æ·Î¸¦ ¾Ð¹ÚÇϰųª Ä§¹üÇϴ º´¿¡¼­ »ý±æ ¼öµµ ÀÖÀ¸¸ç, ¶Ç´Â Æó¾ÏÀ̠ô¼ö¿¡¼­ ºüÁ®³ª¿Í ¸ñºÎºÐ¿¡¼­ ÀÌ·é ±³°¨½Å°æÀÇ Áٱ⸦ ´©¸¦ °æ¿ì¿¡µµ »ý±æ ¼öµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • adrenogenital syndrome
    ºÎ½Å»ý½Ä±âÁõÈıº
  • adult respiratory distress syndrome
    ¼ºÀÎÈ£Èí°ï¶õÁõÈıº
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • afferent loop syndrome
    µéâÀÚÁõÈıº
  • Albright¡¯s syndrome
    ¿Ãºê¶óÀÌÆ®ÁõÈıº
  • Alport syndrome
    ¾ËÆ÷Æ®ÁõÈıº
  • alveolar hypoventilation syndrome
    ÆóÆ÷Àúȯ±âÁõÈıº
  • abstinence syndrome
    ±Ý´ÜÁõÈıº
  • amnestic syndrome
    ±â¾ï»ó½ÇÁõÈıº
  • amniotic band syndrome
    ¾ç¸·¶ìÁõÈıº
  • Barth syndrome
    ¹Ù¸£Æ®ÁõÈıº
  • Bartter¡¯s syndrome
    ¹ÙÅÍÁõÈıº
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • battered child syndrome
    ÇÇÇÐ´ë¾ÆÁõÈıº, ¸Å¸Â´Â¾ÆÀÌÁõÈıº
  • Beckwith¡¯s syndrome
    º¤À§½ºÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • respiratory disturbance syndrome
    È£ÈíÀå¾ÖÁõÈıº
  • retraction syndrome
    ¾È±¸ÈÄÅðÁõÈıº
  • severe acute respiratory syndrome
    ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
  • Sheehan's syndrome
    ½¬ÇÑÁõÈıº
  • short bowel syndrome
    ªÀºÃ¢ÀÚÁõÈıº
  • sick building syndrome
    ºôµùÁõÈıº
  • Sjogren syndrome
    ¼î±×·»ÁõÈıº
  • Stevens-Johnson syndrome
    ½ºÆ¼ºì½ºÁ¸½¼ÁõÈıº
  • subacromial syndrome
    ºÀ¿ì¸®¹ØÁõÈıº, °ßºÀÇÏÁõÈıº
  • sudden infant death syndrome
    ¿µ¾Æ±Þ»çÁõÈıº
  • superior vena caval syndrome
    À§´ëÁ¤¸ÆÁõÈıº, »ó´ëÁ¤¸ÆÁõÈıº
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • tarsal tunnel syndrome
    ¹ß¸ñ±¼ÁõÈıº, Á·±Ù°üÁõÈıº
  • testicular feminization syndrome
    °íȯ¿©¼ºÈ­ÁõÈıº
  • thoracic outlet syndrome
    °¡½¿¹®ÁõÈıº, Èä°ûÃⱸÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • anginal syndrome
    Çù½ÉÁõÁõÈıº
  • angioosteohypertrophy syndrome
    Ç÷°ü»ÀºñÈÄÁõÈıº
  • anterior interosseous nerve syndrome
    ¾Õ»À»çÀ̽ŰæÁõÈıº
  • anterior spinal artery occlusion syndrome
    ¾Õô¼öµ¿¸ÆÆó»öÁõÈıº
  • antibody deficiency syndrome
    Ç×ü°áÇÌÁõÈıº
  • anxiety syndrome
    ºÒ¾ÈÁõÈıº
  • aortic arch syndrome
    ´ëµ¿¸ÆÈ°ÁõÈıº
  • apallic syndrome
    ´ë³ú°ÑÁú»ó½ÇÁõÈıº
  • aqueous mis-direction syndrome
    ¹æ¼öÈ帧ÀÌ»óÁõÈıº
  • asphyctic syndrome
    Áú½ÄÁõÈıº
  • atomic bomb syndrome
    ¿øÀÚÆøÅºÁõÈıº
  • auriculotemporal syndrome
    ±Ó¹ÙÄû°üÀÚÁõÈıº
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • battered child syndrome
    ¸Å¸Â´Â¾ÆÀÌÁõÈıº
  • biochemical defect syndrome
    »ýÈ­ÇÐÀû°áÇÔÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Chauffard-Still syndrome
    ¼îÆÄ¸£-½ºÆ¿ÁõÈıº.
  • Chediak-Higashi syndrome
    ¼¼µð¾ÆÅ©-È÷°¡½Ã ÁõÈıº
  • Chediak-Higashi syndrome
    ¼¼µð¾ÆÅ©-È÷°¡½ÃÁõÈıº.
  • Chilaiditis syndrome
    ų¶óÀ̵ðƼÁõÈıº.
  • Chronic fatigue syndrome
    ¸¸¼ºÇÇ·Î ÁõÈıº
  • Churg-Strauss syndrome
    Ãʱ×-½ºÅä¶ó¿ì½º ÁõÈıº
  • Cockayne syndrome
    ÄÚÄÉÀÎ ÁõÈıº(~ ñøý¦ÏØ)
  • Cockaynes syndrome
    ÄÚÄÉÀÎ ÁõÈıº
  • Coffin-Lowry syndrome
    ÄÚÇÉ-·Î¸® ÁõÈıº
  • Coffin-Siris syndrome
    ÄÚÇÉ-½Ã¸®½º ÁõÈıº
  • Cogan-Reese syndrome
    ÄÚ°£-¸®½ºÁõÈıº
  • Conn syndrome
    ÄÜÁõÈıº
  • Conns syndrome
    ÄÜÁõÈıº.
  • Conradi syndrome => chondrodysplasia calcificans congenita
    ¼±Ãµ¼º Ä®½·È­ ¿¬°ñ ÀÌÇü¼º
  • Conradi-Hunermann syndrome => chondrodysplasia punctata, autosomal dom
    »ó¿°»öü ¿ì¼ºÇü Á¡»ó¿¬°ñ ÀÌÇü¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è(ìúßÉ-Ü»×âùÊîÜ ßÓû»Î¼Ìõ)
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • mycology, clinical
    ÀÓ»óÁø±ÕÇÐ
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • structured clinical interview
    ±¸Á¶È­µÈ ÀÓ»ó¸éÁ¢(ìúßÉØüïÈ).
  • validity of clinical study
  • angry back syndrome => excited skin syndrome
  • syndrome, Steiners [=curtius syndrome, facial hem
    ¾È¸é¹Ý(ÂÊ)ºñ´ëÁõ
  • abdominal muscle deficiency syndrome
    º¹±Ù°á¼ÕÁõÈıº(ÜÙÐÉÌÀáßñøý¦ÏØ).
  • absent pulmonary valve syndrome
    Æóµ¿¸ÆÆÇ°á¿©Áõ.
  • absent pulmonary valve syndrome
    Æóµ¿¸ÆÆÇ°á¿©Áõ.
  • absent testes syndrome
    °íȯ°á¿©ÁõÈıº
  • abstinence syndrome
    ±Ý´ÜÁõÈıº(Ð×Ó¨ñøý¦ÏØ).
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • straight back syndrome
    Á÷ôÃßÁõ
  • temporal lobe syndrome
    ÃøµÎ¿±ÁõÈıº
  • trisomy 18 syndrome
    18¹ø»ï¿ª»öüÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HS Haber syndrome; half strength; hamstring; hand surgery; Hartmann solution; head sling; healthy subje...
KS Kallmann syndrome; Kaposi sarcoma; Kartagener syndrome; Kawasaki syndrome; keratan sulfate; ketoster...
RS radioscaphoid; random sample; rating schedule; Raynaud syndrome; recipient's serum; rectal sinus; re...
ACS acrocallosal syndrome; acrocephalosyndactyly; acute chest syndrome; acute confusional state; Alcon C...
CES carboxylesterase; cauda equina syndrome; cat's eye syndrome; central excitatory state; chronic elect...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CIS Clinical Interview Schedule
CLIA Clinical Laboratory Improvement Amendment
CLIA Clinical Laboratory Improvement Amendments of 1988
CLIA '88 Clinical Laboratory Improvement Amendments of 1988
CLS Clinical Laboratory Science
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Alström's syndrome
    ¾Ë½ºÆ®·Ý ÁõÈıº
    »ö¼Ò¼º ¸Á¸·¿°°ú ¾ÈÁø, Á¶±â Áß½É¿Í ½Ã·Â »ó½Ç, ³­Ã», ºñ¸¸ ¹× ´ç´¢º´À» ³ªÅ¸³»´Â ¼±Ãµ¼º ÁõÈıº.
  • alveolar hypoventilation syndrome
    ÆóÆ÷ Àúȯ±â ÁõÈıº
  • alveolar-capillary block syndrome
    ÆóÆ÷-¸ð¼¼Ç÷°ü Â÷´Ü ÁõÈıº
  • amelo-cerebro-hypohidrotic syndrome
    ¿¡³ª¸á-´ë³ú-¶¡°ú¼Ò ÁõÈıº
  • amphorometallic syndrome
    °øµ¿ ±Ý¼Ó¼º ÁõÈıº
    Æó ÇãÅ» ¼ö¼ú ÈÄ ³ªÅ¸³ª´Â È£ÈíÀ½ÀÇ °øÈ£¼º, ¿µÀ½¼º ÁõÈıº.
  • androgen insensitivity syndrome
    ¾Èµå·Î°Õ ºÒ°¨¼º ÁõÈıº
  • androgen resistance syndrome
    ³²¼º È£¸£¸ó ³»¼º ÁõÈıº, ³²¼º È£¸£¸ó ÀúÇ× ÁõÈıº
  • Angelmans syndrome
    ¾Þ°Ö¸¸ ÁõÈıº
  • anginal syndrome
    Çù½ÉÁõ ÁõÈıº
  • anorexia-cachexia syndrome
    ½Ä¿å ºÎÁø-¾Ç¾×Áú ÁõÈıº
    ½Ä¿å ºÎÁø°ú ¾Ç¾×Áú°£¿¡ ¾ÆÁ÷ ¹àÇôÁöÁö ¾ÊÀº ¾î¶² °ü°è¿¡¼­ ÀϾ´Â ¾ÏÀÇ Àü½Å Áõ»óÀ¸·Î¼­ ¿µ¾ç½ÇÁ¶, üÁß °¨¼Ò, ±ÙÀ° Çã¾à, »ê¼ºÁõ ¹× Áßµ¶ÁõÀÌ Æ¯Â¡ÀÌ´Ù. ½Ä¿å ºÎÁøÀ» ÀÏÀ¸Å°´Â ±Ù°Å·Î´Â ½ÉÇÑ ´ÙÀμº ½ÅÁø´ë»çÀÇ Àå¾Ö°¡ ¾Ç¾×Áú¼º ¼Ò¸ð¸¦ ÀÏÀ¸Å°´Â µ¥ °ü¿©ÇÑ´Ù°í »ý°¢µÈ´Ù. µû¶ó¼­ ½Ã»ó ÇϺο¡ ÀÖ´Â Æ÷¸¸ ÁßÃ߸¦ Á¾¾ç¿¡¼­ ºÐºñµÇ´Â ½Ä¿åºÎÁø È£¸£¸óÀÌ ÀÚ±ØÇÏ¿© ½Ä¿åÀ» ¾ø¾Ö ½Ä¿åºÎÁøÀ» ÀÏÀ¸Å²´Ù´Â °ÍÀÌ´Ù.
  • anterior choroidal artery occlusion syndrome
    Àü¸Æ¶ô Ãѵ¿¸Æ Æó¼â ÁõÈıº
  • anterior cornual syndrome
    Àü°¢ ÁõÈıº
    ô¼ö Àü°¢ÀÇ »óÇØ¸¦ ³ªÅ¸³»°í, ¿îµ¿ ¸¶ºñ¿Í ±Ù À§ÃàÀÌ Æ¯Â¡ÀÌ´Ù.
  • anterior spinal artery syndrome
    Àüô¼ö µ¿¸Æ ÁõÈıº
  • anterior spinal syndrome
    Àü»è ÁõÈıº
  • anticholinergic syndrome
    Ç×Äݸ°¼º ÁõÈıº
    °æÁõ °íÇ÷¾Ð°ú ºó¸ÆÀÌ ÀϹÝÀûÀ̸ç, ü¿ÂÀº ÈçÈ÷ »ó½ÂµÈ´Ù. µ¿°øÀº ±¤¹üÀ§ÇÏ°Ô È®ÀåµÇ¾î ÀÖ´Ù. ÇǺδ ¹ßÀûµÇ¾î ÀÖ°í ¶ß°Ì°í °ÇÁ¶ÇÏ´Ù. Àå ¿îµ¿Àº °¨¼ÒÇÏ°í ¿ä Á¤Ã¼
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
clinical thermometer A small, self-registering thermometer, consisting of a simple scaled glass tube containing mercury, used for taking the temperature of the body.
(05 Mar 2000)
clinical trial <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.
(12 May 1997)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
controlled clinical trials Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials.
(12 Dec 1998)
cytogenetics, clinical The application of cytogenetics to clinical medicine. For example, clinical cytogenetic studies might be done to determine whether a child with possible Down syndrome has an extra chromosome 21.
(12 Dec 1998)
prospective, randomised, double-blind clinical trial <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient.
(13 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á